Article United Biosource News Today

12/06/21 Clinical Leader Newsletter

02.24.21 -- Insource, Outsource, Or Both? Choosing The Right Model For Your Clinical Workforce     Orphan drugs are notorious for their high costs and risk factors, which are attributed to smaller patient pools and higher development and launch costs. Attend this webinar to learn more about key trends that are causing the rise of orphan drug indications, fast-tracking early development phases that will lead to commercial success, and more! By Mark Shapiro, Ph...